News

Following approval, this product will serve as replacement therapy for patients who suffer from a congenital lack of the normal plasminogen protein and/or its functional activity. The FDA

OliPass is focused on developing antisense medicines based on peptide nucleic acid (PNA) technology. As part of the deal, BMS will make an up-front payment as well as

The company said that ARA 290 activates the natural repair system of the body by activating the Innate Repair Receptor and thereby turning off systemic inflammation and turning

The trial is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses MBC-11, a lead compound from a technology platform based on bisphosphonate

Under the deal, Aspen will be responsible for securing regulatory and pricing approval, as well as the marketing and distribution of the drug. Iroko Pharmaceuticals president and CEO

This patent, along with prior patents issued to Curis, further strengthens the Company’s intellectual property portfolio of compounds including CUDC-907 that inhibit HDAC and PI3K enzymes in a

The study was first presented to the scientific community on October 14, 2014 at the World Vaccine Congress in Brussels, Belgium by Vaxart. WCCT Global conducted this phase

The randomized, double-blind, placebo-controlled study, known as "EASE LID 3," is planned to enroll approximately 70 patients with LID. The 13-week study will include an estimated 35 sites

Fleet’s management team, along with several additional investors, will hold minority stakes alongside Gryphon. Fleet Laboratories, headquartered in Lynchburg, VA and family-owned since its founding in 1869, is